US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven said the FDA imposed a partial clinical hold on its experimental epilepsy drug trials, halting new patient enrollment following rodent-study findings. Shares fell more than 13% in premarket trading, reflecting heightened regulatory and development risk for the program.